Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005232022> ?p ?o ?g. }
Showing items 1 to 90 of
90
with 100 items per page.
- W2005232022 abstract "CTRC-AACR San Antonio Breast Cancer Symposium: 2008 AbstractsAbstract #64 Background Following the Women's Health Initiative (WHI) estrogen plus progestin (E+P) trial report (JAMA 2002;288:321), menopausal hormone therapy use decreased dramatically in the United States. Subsequently, breast cancer incidence also dropped substantially, suggesting possible causality (NEJM 2007;16:1680); however, the etiology remains controversial. Methods To define effects of stopping E+P on breast cancer incidence more precisely, additional analyses were conducted in the WHI randomized trial of daily conjugated equine estrogens (CEE, 0.625 mg) plus medroxyprogesterone acetate (MPA, 2.5 mg) versus placebo. Furthermore, temporal trends for breast cancer diagnoses in the WHI observational study cohort were examined. Breast cancer risk factors, mammography utilization and calendar time-specific breast cancer incidence were assessed relative to E+P use. Results: The time-specific linear hazard ratio (HR) curves examining E+P influence on breast cancer in the E+P clinical trial (CT), and in the observational study (OS, the later adjusted for E+P use during follow-up) are attached. ![][1] ![][2] In the CT, breast cancer incidence, initially lower in the E+P group, increased with longer duration use but decreased postintervention despite closely comparable mammogram frequency between randomization groups. In the OS, breast cancer incidence was about two-fold higher in E+P users vs non-users (likely reflecting longer duration exposure) but decreased rapidly following year-to-year reductions in E+P use, while differences in mammogram frequency between E+P users and non-users were unchanged. Conclusion: These findings suggest that cessation of E+P use is associated with a rapid reduction in breast cancer incidence which is not explained by mammography utilization change and support the hypothesis that the recent reduction in breast cancer incidence seen in certain age groups is predominantly related to a decrease in combined menopausal therapy use.Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 64. [1]: /embed/graphic-1.gif [2]: /embed/graphic-2.gif" @default.
- W2005232022 created "2016-06-24" @default.
- W2005232022 creator A5004131578 @default.
- W2005232022 creator A5007771439 @default.
- W2005232022 creator A5010777209 @default.
- W2005232022 creator A5024489311 @default.
- W2005232022 creator A5029524242 @default.
- W2005232022 creator A5041029564 @default.
- W2005232022 creator A5055140948 @default.
- W2005232022 creator A5058664760 @default.
- W2005232022 creator A5067389037 @default.
- W2005232022 creator A5081009904 @default.
- W2005232022 date "2009-01-15" @default.
- W2005232022 modified "2023-09-27" @default.
- W2005232022 title "Breast cancer after stopping estrogen plus progestin in postmenopausal women in the women's health initiative." @default.
- W2005232022 doi "https://doi.org/10.1158/0008-5472.sabcs-64" @default.
- W2005232022 hasPublicationYear "2009" @default.
- W2005232022 type Work @default.
- W2005232022 sameAs 2005232022 @default.
- W2005232022 citedByCount "0" @default.
- W2005232022 crossrefType "proceedings-article" @default.
- W2005232022 hasAuthorship W2005232022A5004131578 @default.
- W2005232022 hasAuthorship W2005232022A5007771439 @default.
- W2005232022 hasAuthorship W2005232022A5010777209 @default.
- W2005232022 hasAuthorship W2005232022A5024489311 @default.
- W2005232022 hasAuthorship W2005232022A5029524242 @default.
- W2005232022 hasAuthorship W2005232022A5041029564 @default.
- W2005232022 hasAuthorship W2005232022A5055140948 @default.
- W2005232022 hasAuthorship W2005232022A5058664760 @default.
- W2005232022 hasAuthorship W2005232022A5067389037 @default.
- W2005232022 hasAuthorship W2005232022A5081009904 @default.
- W2005232022 hasConcept C120665830 @default.
- W2005232022 hasConcept C121332964 @default.
- W2005232022 hasConcept C121608353 @default.
- W2005232022 hasConcept C126322002 @default.
- W2005232022 hasConcept C143998085 @default.
- W2005232022 hasConcept C207103383 @default.
- W2005232022 hasConcept C23131810 @default.
- W2005232022 hasConcept C2776306185 @default.
- W2005232022 hasConcept C2777164284 @default.
- W2005232022 hasConcept C2780275930 @default.
- W2005232022 hasConcept C2780733421 @default.
- W2005232022 hasConcept C29456083 @default.
- W2005232022 hasConcept C44249647 @default.
- W2005232022 hasConcept C530470458 @default.
- W2005232022 hasConcept C61511704 @default.
- W2005232022 hasConcept C71924100 @default.
- W2005232022 hasConceptScore W2005232022C120665830 @default.
- W2005232022 hasConceptScore W2005232022C121332964 @default.
- W2005232022 hasConceptScore W2005232022C121608353 @default.
- W2005232022 hasConceptScore W2005232022C126322002 @default.
- W2005232022 hasConceptScore W2005232022C143998085 @default.
- W2005232022 hasConceptScore W2005232022C207103383 @default.
- W2005232022 hasConceptScore W2005232022C23131810 @default.
- W2005232022 hasConceptScore W2005232022C2776306185 @default.
- W2005232022 hasConceptScore W2005232022C2777164284 @default.
- W2005232022 hasConceptScore W2005232022C2780275930 @default.
- W2005232022 hasConceptScore W2005232022C2780733421 @default.
- W2005232022 hasConceptScore W2005232022C29456083 @default.
- W2005232022 hasConceptScore W2005232022C44249647 @default.
- W2005232022 hasConceptScore W2005232022C530470458 @default.
- W2005232022 hasConceptScore W2005232022C61511704 @default.
- W2005232022 hasConceptScore W2005232022C71924100 @default.
- W2005232022 hasLocation W20052320221 @default.
- W2005232022 hasOpenAccess W2005232022 @default.
- W2005232022 hasPrimaryLocation W20052320221 @default.
- W2005232022 hasRelatedWork W1979932009 @default.
- W2005232022 hasRelatedWork W1991371099 @default.
- W2005232022 hasRelatedWork W2013323189 @default.
- W2005232022 hasRelatedWork W2052824750 @default.
- W2005232022 hasRelatedWork W2077579184 @default.
- W2005232022 hasRelatedWork W2105532195 @default.
- W2005232022 hasRelatedWork W2121062750 @default.
- W2005232022 hasRelatedWork W2137538514 @default.
- W2005232022 hasRelatedWork W2142696583 @default.
- W2005232022 hasRelatedWork W2148120400 @default.
- W2005232022 hasRelatedWork W2151208412 @default.
- W2005232022 hasRelatedWork W2314563621 @default.
- W2005232022 hasRelatedWork W2400208827 @default.
- W2005232022 hasRelatedWork W2414845608 @default.
- W2005232022 hasRelatedWork W2794190040 @default.
- W2005232022 hasRelatedWork W2935812534 @default.
- W2005232022 hasRelatedWork W2955696602 @default.
- W2005232022 hasRelatedWork W3013390527 @default.
- W2005232022 hasRelatedWork W3045747832 @default.
- W2005232022 hasRelatedWork W1964539564 @default.
- W2005232022 isParatext "false" @default.
- W2005232022 isRetracted "false" @default.
- W2005232022 magId "2005232022" @default.
- W2005232022 workType "article" @default.
!["CTRC-AACR San Antonio Breast Cancer Symposium: 2008 AbstractsAbstract #64 Background Following the Women's Health Initiative (WHI) estrogen plus progestin (E+P) trial report (JAMA 2002;288:321), menopausal hormone therapy use decreased dramatically in the United States. Subsequently, breast cancer incidence also dropped substantially, suggesting possible causality (NEJM 2007;16:1680); however, the etiology remains controversial. Methods To define effects of stopping E+P on breast cancer incidence more precisely, additional analyses were conducted in the WHI randomized trial of daily conjugated equine estrogens (CEE, 0.625 mg) plus medroxyprogesterone acetate (MPA, 2.5 mg) versus placebo. Furthermore, temporal trends for breast cancer diagnoses in the WHI observational study cohort were examined. Breast cancer risk factors, mammography utilization and calendar time-specific breast cancer incidence were assessed relative to E+P use. Results: The time-specific linear hazard ratio (HR) curves examining E+P influence on breast cancer in the E+P clinical trial (CT), and in the observational study (OS, the later adjusted for E+P use during follow-up) are attached. ![][1] ![][2] In the CT, breast cancer incidence, initially lower in the E+P group, increased with longer duration use but decreased postintervention despite closely comparable mammogram frequency between randomization groups. In the OS, breast cancer incidence was about two-fold higher in E+P users vs non-users (likely reflecting longer duration exposure) but decreased rapidly following year-to-year reductions in E+P use, while differences in mammogram frequency between E+P users and non-users were unchanged. Conclusion: These findings suggest that cessation of E+P use is associated with a rapid reduction in breast cancer incidence which is not explained by mammography utilization change and support the hypothesis that the recent reduction in breast cancer incidence seen in certain age groups is predominantly related to a decrease in combined menopausal therapy use.Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 64. [1]: /embed/graphic-1.gif [2]: /embed/graphic-2.gif"](?object=%22CTRC-AACR%20San%20Antonio%20Breast%20Cancer%20Symposium%3A%202008%20AbstractsAbstract%20%2364%20Background%20Following%20the%20Women's%20Health%20Initiative%20(WHI)%20estrogen%20plus%20progestin%20(E%2BP)%20trial%20report%20(JAMA%202002%3B288%3A321)%2C%20menopausal%20hormone%20therapy%20use%20decreased%20dramatically%20in%20the%20United%20States.%20Subsequently%2C%20breast%20cancer%20incidence%20also%20dropped%20substantially%2C%20suggesting%20possible%20causality%20(NEJM%202007%3B16%3A1680)%3B%20however%2C%20the%20etiology%20remains%20controversial.%20Methods%20To%20define%20effects%20of%20stopping%20E%2BP%20on%20breast%20cancer%20incidence%20more%20precisely%2C%20additional%20analyses%20were%20conducted%20in%20the%20WHI%20randomized%20trial%20of%20daily%20conjugated%20equine%20estrogens%20(CEE%2C%200.625%20mg)%20plus%20medroxyprogesterone%20acetate%20(MPA%2C%202.5%20mg)%20versus%20placebo.%20Furthermore%2C%20temporal%20trends%20for%20breast%20cancer%20diagnoses%20in%20the%20WHI%20observational%20study%20cohort%20were%20examined.%20Breast%20cancer%20risk%20factors%2C%20mammography%20utilization%20and%20calendar%20time-specific%20breast%20cancer%20incidence%20were%20assessed%20relative%20to%20E%2BP%20use.%20Results%3A%20The%20time-specific%20linear%20hazard%20ratio%20(HR)%20curves%20examining%20E%2BP%20influence%20on%20breast%20cancer%20in%20the%20E%2BP%20clinical%20trial%20(CT)%2C%20and%20in%20the%20observational%20study%20(OS%2C%20the%20later%20adjusted%20for%20E%2BP%20use%20during%20follow-up)%20are%20attached.%20!%5B%5D%5B1%5D%20!%5B%5D%5B2%5D%20In%20the%20CT%2C%20breast%20cancer%20incidence%2C%20initially%20lower%20in%20the%20E%2BP%20group%2C%20increased%20with%20longer%20duration%20use%20but%20decreased%20postintervention%20despite%20closely%20comparable%20mammogram%20frequency%20between%20randomization%20groups.%20In%20the%20OS%2C%20breast%20cancer%20incidence%20was%20about%20two-fold%20higher%20in%20E%2BP%20users%20vs%20non-users%20(likely%20reflecting%20longer%20duration%20exposure)%20but%20decreased%20rapidly%20following%20year-to-year%20reductions%20in%20E%2BP%20use%2C%20while%20differences%20in%20mammogram%20frequency%20between%20E%2BP%20users%20and%20non-users%20were%20unchanged.%20Conclusion%3A%20These%20findings%20suggest%20that%20cessation%20of%20E%2BP%20use%20is%20associated%20with%20a%20rapid%20reduction%20in%20breast%20cancer%20incidence%20which%20is%20not%20explained%20by%20mammography%20utilization%20change%20and%20support%20the%20hypothesis%20that%20the%20recent%20reduction%20in%20breast%20cancer%20incidence%20seen%20in%20certain%20age%20groups%20is%20predominantly%20related%20to%20a%20decrease%20in%20combined%20menopausal%20therapy%20use.Citation%20Information%3A%20Cancer%20Res%202009%3B69(2%20Suppl)%3AAbstract%20nr%2064.%20%5B1%5D%3A%20%2Fembed%2Fgraphic-1.gif%20%5B2%5D%3A%20%2Fembed%2Fgraphic-2.gif%22){kind=link}